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OBJECTIVE 
To study the incidence of facial nerve palsy post operatively in patients 
undergoing surgical treatment of benign parotid tumors 
 
METHODS 
This was a prospective, randomized interventional study wherein 36 patients with 
benign parotid tumors were included and randomized into two groups: Superficial 
Parotidectomy and Extracapsular Excision.  Post operatively, the facial nerve 
function was assessed by the House-Brackmann Score on post operative days 2, 7 
and 10 and compared between the two groups.    
 
RESULTS 
 Post operatively, there was no significant difference between the two operations 
with regard to facial nerve palsy. 
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INTRODUCTION 
 
 The current standard of treating benign parotid tumors is by means of 'Superficial 
Parotidectomy', which entails removal of the entire superficial parotid gland with 
exposure of the facial nerve branches. This leads to increased incidence of facial nerve 
palsy which is a debilitating condition to the patient. Newer research is aimed at more 
conservative approaches towards parotidectomy by selective and meticulous excision 
of the lesion to prevent the aforementioned complication and to effectively remove 
the tumour with only a little but adequate margin of normal tissue, without 
compromising onco-surgical principles.  In this research, we aim to observe the 
complications of an alternative procedure called 'extracapsular excision' in treating 
benign parotid tumors as compared to superficial parotidectomy.   In this way, we 
attempted to evaluate whether extracapsular excision provides additional benefit to 
patients as compared to superficial parotidectomy.  
  
 
 
12 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVES 
  
 
 
13 
 
AIM AND OBJECTIVES 
AIM 
To assess the early post operative sequelae of  extracapsular excision versus the 
standard superficial parotidectomy in the treatment of benign parotid tumors 
restricted to the superficial lobe.   
OBJECTIVES  
1. To compare the incidence of facial nerve palsy between extracapsular 
excision and superficial parotidectomy in the early post operative period.  
2. To compare the positive margins associated with extracapsular excision and 
superficial parotidectomy.  
3.  To assess the feasibility of extracapsular excision as a standard procedure 
in the treatment of benign parotid tumors..  
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REVIEW OF LITERATURE 
 
ANATOMY OF THE PAROTID GLAND 
 Salivary glands are divided into major and minor, the major being the 
paired parotid, submandibular and sublingual glands. The minor glands include 
numerous small glands which outline the upper aero-digestive tract. (1) 
 The Parotid gland is the largest of the salivary glands. It overlies the angle 
of the mandible. It is closely related to the parapharyngeal space medially, the 
cartilage of the ear canal posteriorly, the zygoma superiorly and the posterior 
belly of the digastric and sternomastoid muscles inferiorly. (1) 
 The facial nerve traverses through the parotid gland after it exits  the 
stylomastoid foramen and divides into  5 main branches within the substance of 
the parotid gland. The pattern of branching is variable. The plane of the facial 
nerve divides the gland into superficial and deep lobes, with normally 80% of the 
gland being superficial and the remaining part of the gland being deep to the 
nerve. (2) 
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Embryology: 
 In the 6th to 8th week of development, outpouchings extend from the oral 
ectoderm into the adjacent mesoderm that serve as the sites for the origin of the 
major salivary glands. There are three stages of development of the major salivary 
glands.(3,4) 
 Stage 1: Development of primordial anlage, and progressive epithelial cleft 
 and bud development that leads to branched duct bud formation. 
 Stage 2: The first appearance of lobules and duct canalization. Primitive 
 acini lined by myoepithelial cells are formed by 7th month of embryonic 
 life. (5) 
 Stage3: Maturation of the acini and intercalated ducts and depression of 
 the interstitial tissue.  
 The parotid gland appears first among the major salivary glands, during the 
6th gestational week; the posterior stomodeum elongates laterally to form solid 
cords which travel across the developing masseter muscle to form ducts, with the 
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distal ends forming acini. At the same time, a capsule formed by the pre-existing 
mesenchyme surrounds the gland and associated lymph nodes. (6) 
 The submandibular gland is represented by small buds around  the 6th 
week. These appear lateral to the tongue at the floor of the mouth to extend 
posteriorly around the mylohyoid into the submandibular triangle. The sublingual 
gland develops around the 9th month from multiple endodermal epithelial buds 
at the floor of the mouth in the paralingual sulcus. The minor salivary glands are 
represented by tubo-acinar units developed from upper respiratory ectoderm 
during the 12th intrauterine week. (7) 
Gross Anatomy: 
 The Parotid gland is the largest of all the salivary glands. It is a paired organ, 
weighing about 15-30 g, and is located in the preauricular region along the 
posterior surface of the mandible. It is divided into the superficial and deep lobes 
by the facial nerve.  The facial nerve along with the retromandibular vein lies in 
the  fasciovenous plane of Patey. The superficial lobe is described as being lateral 
to the facial nerve overlying the lateral surface of the masseter, hence is also 
referred to as the lateral lobe. The deep or the medial lobe lies medially between 
the mastoid process of the temporal bone and the ramus of the mandible.  
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 Superiorly, the parotid gland is bound by the zygomatic arch. Inferiorly, the 
tail of the parotid gland extends posteriorly over the superior  border of the 
sternocleidomastoid muscle towards the tip of the mastoid. The deep lobe lies 
within the parapharyngeal space. (2) 
 The parotid gland is covered by the parotid fascia, which is a continuation 
of investing layer of the deep cervical fascia that splits into the superficial and 
deep laminae to enclose the gland. The parotid fascia itself is dense and inelastic. 
The superficial lamina of the fascia is thicker and extends from the masseter and 
the sternocleidomastoid to the zygomatic arch and to the stylomandibular 
ligament. The stylomandibular ligament is a surgical landmark which also 
separates the superficial and deep lobes of the parotid. Stylomandibular 
tenotomy is a useful technique in en-block resection of the deep parotid lobe or 
other para-pharyngeal tumors.(8) The parotid gland secretes saliva which is more 
serous than mucous. (1) 
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Parotid Duct 
 It exits the parotid gland from its anterior border to travel parallel to the 
zygomatic bone, about 1cm below it, anterior to the masseter. It takes a sharp 
turn at the buccinator muscle to pierce it, and enter the oral cavity opposite to 
the second upper molar tooth.(2)  
Facial Nerve 
 The seventh cranial nerve arises from the pontomedullary junction and 
courses laterally through the cerebellpontine angle (together with the 
vestibulocochlear nerve) to the internal auditory meatus. The nerve then passes 
through the facial canal, passing backwards and downwards to exit through the 
stylomastoid foramen. It then  gives off three motor branches supplying  the 
posterior belly of digastric, stylohyoid and post auricular muscles before entering 
the parotid gland posteriorly. The main trunk divides into two divisions, viz. the 
temporozygomatic and the cervicofacial divisions. The upper temporozygomatic 
division forms the temporal zygomatic and upper buccal branches, while the 
lower cervicofacial division forms the lower buccal, marginal mandibular and 
cervical branches. There may be communications between branches of both 
 
 
20 
 
divisions to form midfacial branches leading to a formation of goose feet or (2)pes 
anserius.  
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Table 1: Facial Nerve: Branches, course and nerve supply 
Branch of Facial Nerve Course Muscles supplied 
Temporal Parallel to superficial 
temporal vessels across 
Zygoma 
Frontal belly of 
occipitofrontalis, 
orbicularis oculi, 
corrugator supercili, 
anterior and superior 
auricular muscles 
Zygomatic Over the periosteum of 
zygomatic arch 
Zygomatic, orbital and 
infraorbital 
Buccal Along Stenson's duct 
over the masseter  
Buccinator, upper lip 
and nostril muscles 
Marginal Mandibular Inferior border of 
Parotid 
Lower lip and chin 
muscles 
Cervical  Within the deep 
cervical fascia, under 
the platysma 
Platysma 
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 In surgical practice, it is possible to trace the branches of the facial nerve in 
the antegrade or in the retrograde fashion. The facial nerve can also be identified 
by performing a mastoidectomy, at its extracrainal exit point, the stylomastoid 
foramen. (2,9,10) 
 Other important nerves in this region include the auriculotemporal nerve 
(ATN) and the great auricular nerve (GAN).  
 The ATN is a branch of the mandibular nerve, the posterior division of the 
Trigeminal (V3). It exits the foramen ovale, runs parallel to the superficial 
temporal vessels, and travels anterior to the external auditory canal to innervate 
the skin and the scalp anterior to the ear. (2) 
 The GAN is a sensory branch from the cervical plexus. It arises mainly from 
C2 and C3, runs parallel to the external jugular vein along the lateral surface of 
the SCM to the tail of the parotid, where it divides into anterior and posterior 
branches. It innervates the posterior aspect of the pinna and the ear lobule. It is 
commonly sacrificed during parotidectomy, which leads to troublesome sensory 
loss around the ear lobule. A segment of this may be preserved  for facial nerve 
grafting. (2) 
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 The glossopharyngeal nerve provides visceral sensory innervations to the 
parotid gland. Preganglionic parasympathetic fibers are carried by the inferior 
salivary nucleus in the medulla through the jugular foramen. Distal to this 
ganglion the Jacobsen's nerve, i.e. a small branch of the glossopharyngeal nerve 
re-enters the skull through the inferior tympanic canaliculus into the middle ear 
to form the tympanic plexus. The preganglionic fibers then travel along the lesser 
petrosal nerve into the middle cranial fossa and out of the foramen ovale to 
synapse at the otic ganglion. Thence the post ganglionic fibers exit the otic 
ganglion beneath the mandibular nerve to join the auriculotemporal nerve in the 
infratemporal fossa. These fibers are responsible for the secretion of saliva.  
 Sympathetic fibers arise from the superior cervical ganglion through the 
external carotid plexus. Acetylcholine serves as a neurotransmitter for both 
sympathetic and parasympathetic fibers. For this reason, patients may develop 
'gustatory sweating' or Frey's Syndrome following parotidectomy.(11,12) It is 
commonly manifested as sweating and flushing of the skin over the skin over the 
parotid region, due to aberrant re-innervation between the autonomic and 
sympathetic fibers from the residual parotid gland. This can be minimized by 
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meticulous surgical excision of the parotid, or by developing skin flaps of 
appropriate thickness, by which exposed apocrine glands are protected from 
ingrowth and stimulation from the ATN and parasympathetic stimulation during 
meals.  
 
Arterial Supply 
 The arterial supply is by the branches of the external carotid artery (ECA) 
which arises from the carotid bifurcation, travels parallel to the mandible under 
the posterior belly of the digastric muscle. It then travels medial to the parotid to 
split into two branches: The superficial temporal artery (STA) and the internal 
maxillary artery (IMA). The STA travels superiorly from the superior border of the 
parotid in the pre-tragal region to supply the scalp. It gives off a branch, viz. the 
transverse facial artery which travels anteriorly between the parotid duct and the 
Zygoma to supply the parotid, the parotid duct and the masseter. The IMA leaves 
the parotid in the medial aspect to supply the infratemporal and pterygopalatine 
fossae. Control of this vessel is crucial during radical parotidectomy, especially 
when segmental or marginal mandibulectomy is required.   
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Venous Drainage 
 Venous drainage is by the retromandibular vein (RMV), which is formed by 
the union of the maxillary vein and the superficial temporal vein, and drains into 
the external jugular vein.  The RMV travels just below the facial nerve in the 
faciovenous plane of Patey, thus serving as an operative and non-operative 
radiological landmark to distinguish the superficial and deep lobes of the parotid. 
The RMV may give anterior and posterior branches, although this is subject to 
variation. The anterior branch unites with the posterior facial vein to form the 
common facial vein. The posterior facial vein lies immediately deep to the 
marginal mandibular nerve and hence is a landmark to identify the same.(13) The 
posterior branch may join the post auricular vein above the SCM to join the EJV.  
 
Lymphatic Drainage 
 Unlike the other salivary glands, the parotid has a high density of lymph 
nodes within and around the gland. It has two nodal layers which drain into the 
superficial and deep cervical lymph systems. The majority (about 90%) of the 
nodes are located in the superficial layer between the glandular tissue and its 
capsule.  The superficial nodes drain the parotid gland, external auditory canal, 
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pinna, eyelids, lacrimal glands and the scalp, whereas the deep nodes drain the 
deep lobe, external auditory canal (also), middle ear, nasopharynx and the soft 
palate. (14) 
 
PHYSIOLOGY 
 The principal function of the salivary glands is to secrete saliva, which has 
digestive, lubricative and protective functions in the body.  
Secretion 
 Within the gland, potassium [K+] concentration is high and sodium [Na+] 
concentration is low. With increasing flow rate, [K+] concentration decreases 
slightly to level off at a constant value, whereas [Na+] concentration increases. 
Chloride concentration predominantly follows [Na+] concentration. Except at low 
levels of secretion, bicarbonate [HCO3
-] secretion in saliva is hypertonic compared 
to plasma .  
 Within the duct, [Na+] and [Cl-] are reabsorbed, whereas [K+] and [HCO3
-] 
are secreted. At higher flow rates, less time is available for this exchange and 
hence the concentration is isotonic to plasma. At lower flow rates, [K+] is higher in 
 
 
27 
 
saliva, [Na+] and [Cl-] are lower, and [HCO3-] remains hypertonic to plasma. 
Mostly, however, saliva is hypotonic to plasma since [Na+] and[ Cl-] reabsorption is 
greater than secretion of [K+] and [HCO3
-].  
 Saliva also contains the compounds alpha amylase, lingual lipase, 
lysozymes, glycoprotein, IgA secretory piece and lactoferrin which are detailed 
below. Also secreted are organic blood group antigens A, B, AB and O. The protein 
Kallikrein is also secreted by saliva, which converts plasma protein into 
bradykinin.  
 Salivary secretion is regulated by both parasympathetic and sympathetic 
branches, but more by the parasympathetic arm, through the facial and 
glossopharyngeal nerves. It leads to acinar activation and ductal transport, 
leading to glandular vasodilatation and myoepithelial cell contraction. Subsequent 
to AcH stimulation of muscarinic receptors, inositol trisphosphate is formed which 
causing increased Calcium [Ca++] concentration intracellularly. The source of this 
[Ca++] is either from intracellular stores or from plasma. Thus, [Ca++] acts as a 
second messenger which controls the volume of salivary secretion. Further 
secretion is maintained by acetylcholinesterases, which inhibit the breakdown of 
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Acetylcholine (ACh). Atropine, the muscarinic antagonist, decreases salivation by 
competing with (ACh) for the salivary receptors.  
 Sympathetic stimulation is via the superior cervical ganglion. It leads to 
myoepithelial contraction, similar to parasympathetic stimulation. Changes in 
blood flow occur which is biphasic. Initial vasoconstriction occurs due to 
sympathetic stimulation of alpha-adrenergic receptor activation which is followed 
by vasodilatation due to a buildup of vasodilator metabolites. Nor epinephrine 
binds to alpha adrenergic receptors to form cAMP (3'5'Cyclic Adenosine Mono-
phosphate). This leads to protein phosphorylation and enzyme activation, with 
increased mucus content in saliva.  
Antidiuretic hormone (ADH) and Aldosterone affect salivary secretion by 
increasing [K+] concentration and decreasing [Na+] concentration. However, it 
does not affect the rate of secretion.  
 In the unstimulated state, the quantity of saliva secreted amounts to 1 Liter 
per day. Sixty nine percent is contributed by the submandibular glands, 26% by 
parotid, and 5% by the sublingual glands. In the stimulated state, however, 2/3rd 
of the secretion is from the parotid gland. The minor salivary glands produce 7-8% 
of salivary flow regardless of stimulation.  
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 Stimulants of salivary secretion include the presence of food in the mouth, 
chewing and nausea. Inhibitors include sleep, dehydration, fear and fatigue.  
Role in digestion 
 Saliva contains Ptyalin, an alpha-amylase which cleaves the internal alpha-
1,4-glycosidic bonds of starch to form maltose, maltotriose and alpha-limit 
dextrins. Its optimal pH is 7, and rapidly degrades at more acidic pH and readily 
denatures at ph<4. Even so, it remains active to break down up to 75% of the 
carbohydrate content of a meal within the stomach as effective mixing of the 
food with saliva takes place in the confines of the stomach. In the absence of 
Ptyalin, pancreatic amylase breaks down carbohydrates within the small intestine. 
Additionally, the lingual salivary glands secrete lingual lipase, which break down 
triglycerides.  
Role in Lubrication 
 The mucus constituent of saliva facilitates lubrication of food during 
chewing by mixing with saliva. It eases the process of swallowing. It is also 
important to facilitate speech. 
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Role in Protection 
 Saliva has several antibacterial properties. The secretory piece i.e. a binding 
agent (glycoprotein) for IgA forms a complex with IGA which is active against 
bacteria and viruses. Lysozyme in saliva is antibacterial by causing bacterial 
agglutination and by activating autolysin which degrades cell walls. Lactoferrin in 
saliva  is an iron chelator which inhibits the growth of bacteria which require iron 
for survival.(1,7,15)  
  
Other roles 
 Saliva serves as a protective buffer by diluting harmful substances and 
lowering temperature of hot food items. It also helps to clear foul tasting 
substances. In the stomach, it helps to neutralize acid to some extent. Lack of 
salivation, Xerostomia, leads to apthous ulcers, buccal infections and dental 
caries.  
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SALIVARY TUMORS 
 Benign Salivary tumors include pleomorphic adenoma, warthin’s tumour, 
myoepithelioma, monomorphic adenoma, basal cell, oncocytoma, canalicular, 
sebaceous, ductal, papilloma, intraductal, and inverted sialadenoma 
papillaferum.(16) 
 Malignant tumors are less common, and include the following varieties:  
acinic cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, 
polymorphous low grade adenocarcinoma, epithelial myoepithelial carcinoma, 
clear cell nos, basal cell carcinoma, sebaceous carcinoma, oncocytic carcinoma, 
cystadenocarcinoma, salivary duct carcinoma, myoepithelial carcinoma, 
adenocarcinoma nos, and carcinoma ex pleomorphic adenoma. (16) 
 Certain soft tissue hemato-lymphoid tumors like  hemangioma, hodgkin's 
lymphoma, diffuse large b cell lymphoma, extra nodal marginal B cell 
lymphoma are also described.  (16) 
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Figure 3: Site of origin of Salivary Neoplasms   
70 
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General features of Salivary tumors 
They primarily occur in older adults, with a female preponderance. the exception 
is Warthin's tumour (almost exclusively seen in males who are predominantly 
smokers) and high grade carcinomas. Epithelial tumors form more than 80% of all 
salivary tumors. Benign tumors are more common, accounting for about 75% of 
all epithelial tumors.(16) 
Generally,  smaller the gland,  more the chances of malignancy exist. (17) 
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Relationship between the site of 
Primary tumor and frequency of 
malignancy
Site Absolute
Numbers
Percentage 
Frequency
Percentage
Malignant
Parotid 1756 72.9 14.7
Submandibula
r
257 10.7 37
Sublingual 7 0.3 85.7
Minor glands 336 14 46.4
Unknown 54 2.2 -
Eveson JW, Cawson RA: Salivary gland tumours. A review of 2410 
cases with particular reference to histological types, site, age and 
sex distribution. J Pathol 1985; 146:51-58
 
Figure 4: Relationship between tumor and site of malignancy 
 
In children, salivary tumors are even more rare, accounting for about 1.7 to 3%. In 
infants, the most common types are hemangiomas and lymphomas. In older 
children epithelial tumors are more prominent and chances of malignancy are as 
high as 60%. However, most of the malignant tumors in children are of a low 
grade. (17) 
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Incidence of Benign and Malignant 
Salivary Neoplasms
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Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck 
Surg 1986; 8:177-184  
Figure 5: Incidence of benign and malignant salivary neoplasms 
Incidence of Parotid Tumours(18) 
Pinkston JA, Cole P: Incidence rates of salivary gland tumors: results from a 
population-based study. Otolaryngol Head Neck Surg  1999; 120:834-840  
  
 Among 248 incident cases, 84.3% were benign and 15.7% were malignant. 
Eighty-six percent of cases arose in the parotid gland, and 14% arose in the sub 
mandibular gland. The average annual age-adjusted incidence rate per 100,000 
was 4.7 for benign tumors and 0.9 for malignant tumors. (18) 
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THE DIFFERENT PROCEDURES FOR MANAGEMENT OF BENIGN SALIVARY 
TUMOURS  
 Pleomorphic adenoma is the commonest benign salivary gland tumour.(16) 
It is the commonest salivary tumour too, except in children.(16)(19) It is classically 
described as slow growing indolent tumours which can lead to giant sizes if not 
treated. Malignant change can occur in 0.6% of patients (range 0.9% - 14%) of all 
salivary neoplasms and for 11.7% (2.8-42.4%) of all salivary malignancies.(20)  
 They are notorious for recurrence if inadequately removed.(19) This isso 
because of the pleomorphic adenoma (PA) have a pseudo-capsule of compressed 
fibrous tissue.(19)  There are small elongations called buds or pseudopods, which 
permeate through this capsule . This is the reason why a simple enucleation fails 
to clear these pseudopods completely, and hence inadequate removal causes 
recurrence.(19) So, while parotidectomy aims to remove the tumour with an 
adequate margin of normal tissue, the proximity of the tumour to the facial nerve 
determines how much of the tumour can be excised completely.  
 A retrospective study by Webb and Evesion (2001) of 126 primary 
pleomorphic adenomas to correlate capsular characteristics with tumour 
histopathology  showed little co-relation between the capsular thickness and 
 
 
37 
 
cellular structure.(21) It however showed that hypocellular tumours more than 
25mm in size had capsules which were thinner and more vulnerable to rupture 
during surgery.  (21) 
 McGurk et al in their landmark study in 1996 evaluated 476 superfical lobe 
pleomorphic adenomas, 380 treated by extracapsular excision and 95 treated by 
superficial parotidectomy and found no difference in the recurrence rate or 
incidence of facial nerve palsy.(22) Therefore the importance of pseudopods was 
being questioned and the indications to do a more conservative procedure for 
selected cases of superficial parotidectomy were explored.  
 In 1999, Witt in his series of 59 partial parotidectomies showed zero 
incidence of permanent facial nerve paresis or paralysis and nil recurrence.(23) 
Ghosh et al in 2003 evaluated 83 cases of extracapsular excision in which he 
achieved an overall recurrence rate of 6%; however the recurrence rate was 1.8% 
when margins of <1mm was achieved. (24) 
 McGurk analyzed the outcome of 821 consecutive patients with parotid 
tumors treated at one centre over 40 years and with a median 12 years (range 5–
30) follow-up. (22)The tumors were classified as 'simple' (discrete, mobile, < 
4 cm: n=662) and 'complex' (deep, fixed, facial nerve palsy, 4 cm: n=159). Among 
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the 'simple' or clinically benign tumors, 503 patients underwent ECD and 159 
patients underwent SP.  The margin was taken 2-3mm away from the 
tumour.(22)As far as recurrence was concerned, of the 630 patients with ‘simple’ 
lumps and benign histologies, there were 10 recurrences at 15 years. Eight 
recurrences occurred after 491 ECDs (1.7% at 15 years by life-table analysis); two 
recurrences occurred after 139 SPs (1.8% at 15 years by life-table analysis). In all, 
32 (5%) clinically benign cases were subsequently revealed as malignant 
histologies.  
 For each group, 5- and 10-year cancer-specific survival rates were 100 and 
98% 
 There were no differences in recurrence rates when subanalysed by 
surgical groups, but ECD was associated with significantly reduced morbidity (P < 
0.001) 
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Incidence of Facial Nerve Palsy
Facial Nerve 
Palsy
ECD (n = 491) SP (n=139) P-value
Permanent 8 (1.6%) 2 (1.4%) Not
Significant
Transient 48 (10%) 45 (32%) <0.001
Extracapsular dissection for clinically benign parotid lumps: reduced morbidity 
without oncological compromise M McGurk1, B L Thomas1 and A G Renehan2British 
Journal of Cancer (2003) 89, 1610–1613. doi:10.1038/sj.bjc.6601281
 
Figure 6: Incidence of Facial Nerve Palsy 
 
 Witt, Retjo et al published a series of 59 partial parotidectomies with 
selective nerve dissection for benign and low grade malignant tumors and showed 
zero incidence of permanent facial paresis or paralysis and recurrence.(25) 
 
 Ghosh S, Panarese et al published a series of 83 cases of Extracapsular 
dissection with an overall recurrence rate of 6%. The primary findings were that 
recurrence rate was 17.6% with close margins, whereas the recurrence rate 
dropped to 1.8% when a margin greater than 1mm was achieved. It also showed 
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that intraoperative capuslar rupture and micro-invasion had no influence on 
recurrence. This suggests that only tumors which actually involve the margin are 
at risk for recurrence.(24) This is an important statement with regard to our study 
with close margins.  
  
IN DEPTH ANALYSIS OF KEY STUDIES 
Extracapsular dissection for clinically benign parotid lumps: reduced morbidity 
without oncological compromise. 
M McGurk, BL Thomas and AG Renehan 
 This study was published in 2003 and analysed outcome of patients with 
parotid tumours treated at one center in London, UK over 40 years. Both benign 
and malignant parotid tumors were studied, with emphasis on analyzing viability 
of Extracapsular Dissection in management of patients with bnign parotid tumors.  
For the purpose of this thesis, the terms "Extracapsular Excision" and 
"Extracapsular Dissection" are used interchangeably.    
Methods: For a period between 1952 and 1992, 821 patients with a parotid 
swelling were clinically evaluated and divided into two groups: simple and 
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complex.  There were no other diagnostic tests done.  Grouping was made solely 
on clinical grounds.  
 Among the simple tumours, 503 patients underwent extracapsular 
dissection and 159 patients underwent superficial parotidectomy.  The decision 
for type of operation was made intraoperatively, after assessing the tumour and 
raising skin flaps.  The difference between extracapsular excision and enucleation 
was in plane of dissection; in ECD it was in a compartment of loose areolar tissue 
about 2-3mm from the tumour, wheras in Enucleation the tumour capsule would 
be breached.  Post operative RT was used for patients with tumour spillage of 
benign tumour or for malignant tumours with positive margins, tumours spillage, 
high grade histology or adenoid cystic carcinoma.  
Results:  
 Out of 821 tumours, 662 (81%) were 'simple' lumps out of which 32 (5%) 
were malignant. Out of the 'complex' tumours , 66.66% of tumours were 
malignant.   
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MORBIDITY: 
 ECD (n=491) SP (n=139) P Value 
Permanent Facial 
nerve Palsy 
8 (1.6%) 2 (1.4%) NS 
Transient Facial 
Nerve Palsy 
48 (10%) 45 (32%) <0.001 
Frey's Syndrome 25 (5%) 45 (32%) <0.001 
Salivary Fistula 3 (0.6%) 0 <0.001 
Figure 7: Morbidity of Parotid Operations 
 ECD was associated with less incidence of transient facial palsy as 
compared to SP.  This is expected with less dissection of the facial nerve and its 
branches.  
 Yamashita et al in 1993 analysed 306 cases retrospectively who were 
treated for benign parotid tumour with partial parotidectomy and preservation of 
the facial nerve.  Facial Nerve weakness was observed in 18% of 232 patients on a 
3 year follow up.  (26) 
 Helmus C. in a 10 year review (1985-1994) showed that a subtotal 
parotidectomy was as effective as classic superficial parotidectomy and could 
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provide more advantages, namely a smaller procedure, cost effectiveness, shorter 
operating time and management of such patients on an outpatient or day care 
basis post operatively.  The cosmetic advantages of a smaller scar and lesser 
incidence of Frey's syndrome were also highlighted. (27) 
 Martis in 1983 showed zero incidence of facial nerve palsy 10 year study of 
185 cases with pleomorphic adenoma, out of which in 98 cases (52.6%) 
extracapsular excision was performed.  There was no incidence of permanent 
facial nerve palsy. (28) 
 Prichard AJ et al in 1992 studied the complications of superficial 
parotidectomy versus extracapsular paroitdectomy in the treatment of benign 
parotid lesions.  They evaluated 46 patients with benign parotid lesions, out of 
which 31 (67%) underwent extracapsular excision and 15 (33%) underwent 
superficial parotidectomy.  (29)There was one incidence of permanent facial palsy 
in the superficial parotidectomy versus zero incidence for the extracapsular 
excision group.  
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The House Brackmann Score 
The House Brackmann Score is an objective facial nerve grading system to assess 
the function of the facial nerve. (30) 
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MATERIALS AND METHODS 
 
 The research question raised was : "Is it possible to treat benign superficial 
lobe parotid lesions with a procedure of lesser magnitude that avoids early 
untoward sequalae of superficial parotidectomy while not compromising on 
oncosurgical principles".  We proceeded with a prospective, randomized 
controlled trial to evaluate the role of extracapsular excision in the management 
of benign parotid tumours, specifically the incidence of post operative facial nerve 
palsy.  
 
NULL HYPOTHESIS 
 There is no advantage in terms of early post operative complications 
between superficial parotidectomy and extracapsular excision of benign 
superficial lobe parotid tumours.  
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METHODS 
 Institutional Review Board (IRB) and Ethics Committee approval was 
obtained.  (Appendix 1) 
 All patients diagnosed with superficial parotid tumours were referred to 
our department.  An informed consent was obtained (See Appendix) in the 
patient's local language.   
INCLUSION CRITERIA 
 It was decided to include benign tumors of an acceptable size in both males 
and females. The following were the inclusion criteria:  
1. All patients with a newly diagnosed parotid tumor willing to undergo 
surgery 
2. Tumor Size < 4cm 
3. Benign Parotid Tumors confined to the Superficial Lobe as determined by: 
Clinical Examination, FNAC and Ultrasound 
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EXCLUSION CRITERIA 
1. Diagnosed parotid malignancy 
2. Previous Ipsilateral Parotid Surgery 
3. Tumor Size > 4cm 
4. Deep Lobe Involvement 
5. Recurrent Tumors  
 
SAMPLE SIZE EVALUATION 
 The Sample size was evaluated by a Double Arm Two Proportion Hypothesis 
Tesing (Z Test).  It was calculated with respect to the established incidence of post 
operative facial nerve palsy, which for parotid surgery has a range from 27%- 
100%.  (31–36) 
 The aim was to reduce this incidence to at least 70%.  With a power of 80% 
and an alpha error of 5%, an approximate sample size of 44 patients randomized 
to two groups with 22 patients in each arm was selected.  
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TIME PERIOD 
 A time period of 18 months was estimated for completion of the study.  
PREOPERATIVE EVALUATION  
 All patients underwent a pre-operative evaluation with Clinical 
Examination, FNAC and ultrasonography of the parotid to confirm the location of 
the tumour in the superficial lobe and to confirm the benign nature of the 
swelling.  They also underwent a pre-operative assessment of the facial nerve 
made by a modified House-Brackmann Scoring system. The same scoring system 
was used post operatively.  A record of demographic data and nature of the 
swelling and FNA findings were maintained.  
 The patients were randomized into two groups: Superficial Parotidectomy 
and Extracapsular Excision based on a computerized Randomization Allocation 
software (RALLOC). This randomization code was blinded to the observer and the 
participant of the trial.  
OPERATIONS 
 There were three chief operating surgeons who were involved in each of 
the operations. The participants underwent either Superficial Parotidectomy or 
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Extracapsular Excision based on randomization. In Extracapsular excision, the 
tumor was removed with a 4mm margin of normal parotid tissue.  
Intraoperatively, if it was felt that the tumour appeared malignant or if there was 
involvement of the deep lobe, then the procedure would be abandoned and a 
more extensive resection would be performed.  The consent for the same was 
also obtained pre operatively.  All patients underwent a drain placement post 
operatively.  
SURGICAL TECHNIQUE 
Superficial Parotidectomy 
 The procedure is done under general anaesthesia.  The operation is done 
with the patient in supine position with the neck extended and the head tilted to 
the contra lateral side. The head being draped separately from the body and the 
endotracheal tube is included within the head drape so that adequate 
mobilization of the head could be achieved without compromising the airway.  
The skin incision is started just anterior to the tragus. It proceeds inferiorly till the 
level of the ear lobule and is then angled posteriorly under it. It is then directed 
anteriorly for a suitable distance in the upper neck. It is then carried though the 
skin and the subcutaneous tissue, developing the plane between the cartilaginous 
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external canal and the posterior aspect of the parotid.  The sternomastoid can be 
identified and retracted to dissect the tail of the parotid from this muscle. The 
greater auricular surface may be encountered which may need to be sacrificed.  
This plane is further developed to visualize the posterior belly of the digastric 
below the digastric groove. The anterior flap is elevated in the plane of the  
parotid capsule.  The facial nerve is now identified as its exits the stylomastoid 
foramen. The cartilaginous pointed of the external canal and the tympanomastoid 
sulcus have been identified as pointers to identify the facial nerve.  The main 
trunk is exposed, after which all the branches of the facial nerve are identified 
after careful dissection and the parotid gland superficial to it is excised.  The 
wound is closed and a single closed suction drain may be brought out through a 
separate stab wound. (37) 
 Extracapsular Excision 
 Patient is induced with general anesthesia.  A retro auricular hairline 
incision is done which is cosmetically acceptable.  The incision is angled along the 
subcutaneous fat and sternocleidomastoid muscle to raise anterior skin flaps till 
the lesion is reached.  The parotid capsule and tissue overlying the lesion is 
dissected by producing a margin of at least 4 mm around the lesion.  Loupes are 
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useful in this regard.  Effort is made to avoid capsular rupture and nerve 
exposure.  The tumor is removed completely along with the margin. A suction 
drain is inserted and the wound is closed. (38) 
 
Post operative evaluation 
 The facial nerve status was evaluated by modified House-Brackmann 
Scoring in the immediate post operative period on post op day 2, day 7 and day 
10.  The status of the Temporal, Zygomatic and Buccal facial branches were 
assessed and documented.  The final HPE record was also documented.  
 The data was collected by means of Epidata Software and recorded in 
Microsoft Excel. Analysis of the same was done via Microsoft Excel 2007 and 
STATA Version 10 statistical software.  
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RESULTS 
 A total of 36 participants were recruited into the trial.  They were 
randomized into two groups of 19 and 17 each, with 19 in one group for 
Superficial Parotidectomy (SP) and 17 in the other group for extracapsular 
excision (EC).  
 Out of the 17 patients who underwent extracapsular excision, 2 operations 
had to be converted to superficial parotidectomy. The reasons are as follows: 
 Converted Patient 1: A 3 x 3 cm lesion in the superficial lobe of the left 
 parotid gland with a lobulated extension going deep up to the bony 
 external auditory meatus. 
 Converted Patient 2: A 5 x 3 cm lesion in the superficial lobe of the right 
 parotid gland that extended in the deeper plane. As the tumor size was 
 beyond the inclusion criterion of the study, the operation converted to the 
 standard superficial parotidectomy. 
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Number of Cases analyzed 
 Superficial 
Parotidectomy (SP) 
Extracapsular 
Excision  
(EC) 
Total Patients  
Randomized 
19 17 
Converted to 
Superficial 
Parotidectomy 
NA 2* 
Malignancy in 
Histopathology 
0 2* 
Cases Excluded 0 3* 
Total Cases Analyzed 19 14 
Figure 8: Number of cases analysed 
 
* Out of 2 converted cases, 1 was diagnosed malignant.  The other converted case was 
anatomically not feasible for extracapsular excision.  These cases were excluded from analysis. 
Additionally the second case diagnosed as malignancy was also excluded from analysis. 
 
 Among the 36 participants, two patients (both from extracapsular excision 
group) had surgical histopathology as malignancy.  One of the participants with 
malignancy was the aforementioned 'Converted Patient 2', who was diagnosed 
with low grade mucoepidermoid carcinoma. This patient was kept on follow up 
after the superficial parotidectomy. 
 The second participant with malignancy was diagnosed with papillary 
adenocarcinoma after extracapsular excision. He underwent completion 
parotidectomy at a later date.  
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 For the purpose of the results, both the participants who were diagnosed 
with malignancy in the surgical histopathology were excluded from analysis. The 
one patient from EC group for whom surgery was converted (Converted Patient 1) 
was included, while tabulating the results, in the superficial parotidectomy group.  
Thus, for analysis of data, the results of 33 participants were analyzed, i.e. 19 
patients from SP and 14 patients from EC group.   
 The results were evaluated on several parameters. The preoperative 
evaluation assessed the demographic and clinical features at presentation in 
these patients.  
 The preoperative normal House-Brackmann Score was confirmed in all the 
patients. The post operative House Brackmann Score was analysed on days 2, 7 
and 10. This was compared between the two groups. The results of positive 
margins were recorded and analyzed.  
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DEMOGRAPHIC FEATURES 
 
Out of a target of 44 participants, a total of 33 participants were recruited into 
the study within the given time frame.  
There were 15 male and 18 female participants.   
 
 
 
 
 
 
   
Figure 9: Gender Distribution 
 
Gender 
Male  15 
Female 18 
15 
18 
Gender 
Male  
Female 
Figure 10 Gender Distribution 
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The maximum number of patients were from the 40-49 year age group.  
 
 
Figure 11: Age Distribution Frequency Histogram 
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DURATION OF SYMPTOMS 
The average duration of symptoms at presentation was 3.6 years with a median 
value of 3.5 
years. 
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Figure 12: Duration in Years 
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CLINICAL FEATURES 
Pain was present in one patient. 
 
Figure 13: Pain in participants at randomization 
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The shape was spherical in 31 patients and ill defined in 2 patients. 
 
Figure 14: Shape of the swelling at randomization 
The surface appeared smooth in 16 patients & lobulated in 17 patients. 
 
Figure 15: Surface of swelling at randomization 
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The consistency of the swelling was firm in 32 patients and soft in 1 patient. 
 
Figure 16: Consistency of swelling at randomization 
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FNAC 
All patients underwent an FNAC which was predicted benign nature in 26 cases 
and indeterminate in  10 cases. 
  
TRUE FALSE TOTAL 
Benign 
 
25 1 26 
Malignant 0 1 0 
Indeterminate 
  
10 
 
Figure 17: FNAC Results 
If we assume that the 'Indeterminate' values are all malignant, then there are 26 
benign and 10 malignant diagnoses on FNAC. 
  
TRUE FALSE TOTAL 
Benign 
 
25 1 26 
Malignant 1 9 10 
 
Figure 18: FNAC, Benign and malignant for analysis 
The following results were obtained: 
Sensitivity: 73.53%                       [95% CI: 55.64 % to 87.09 %] 
Specificity: 50%                             [95% CI: 8.17 % to 91.83 %] 
Positive Likelihood Ratio: 1.47   [95% CI: 0.36 to 5.97] 
Negative Likelihood Ratio: 0.53      [95% CI: 0.12 to 2.36] 
Positive Predictive Value: 96.15%  [95% CI: 80.30 % to 99.36 %] 
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Negative predictive Value: 10%      [95% CI: 1.66 % to 44.54 %] 
Margin Status 
The Histopathological margins were assessed based on final biopsy report.  A 
margin of 4mm or more was considered as 'not involved'. A margin less than 4mm 
was considered close.  There were 2 reports in which the margin status was not 
documented by the pathologist.  
MARGIN STATUS 
  SP ECE   TOTAL 
CLOSE 12 9   21 
NOT 
INVOLVED 7 3   10 
DON’T KNOW 0 2   2 
TOTAL 19 14   33 
% CLOSE 63% 64.28%     
 
Figure 19: Margin Status 
P Value = 0.49 
The percentage of close margins in superficial parotidectomy was 63% and that of 
extracapsular excision was 64.28%. The above was not statistically significant.  
  
 
 
65 
 
 
 Score 
 The following are the  Scores of Zygomatic, Temporal and Buccal branches 
on Post Operative Days 2, 7 and 10 respectively. The House-Brackmann Scores 
were divided into Mild (Scores 1 and 2), Moderate (Scores 3 and 4) and Severe 
(Scores 5 and 6).  Since the number of severe scores were minimal, Moderate and 
Severe were combined into one group. Thus, two groups of scores were 
compared as follows: 
Group 1 Mild 
Group 2 Moderate & Severe 
 
HOUSE–BRACKMANN SCORE on Post Operative Day 2 
ZYGOMATIC 
 
Figure 20: Post operative Day 2, Zygomatic 
Pearson CHI2 (1) =   0.5658   P Value = 0.452 
Fisher's exact =                 0.620 
1-sided Fisher's exact =                 0.426 
 
POD 2 Z  SP EC TOTAL
MILD 16 13 29
% 84.21 92.86 87.88
MODERATE & SEVERE 3 1 4
% 15.79 7.14 12.12
TOTAL 19 14 33
100% 100% 100%
 
 
66 
 
 
HOUSE–BRACKMANN SCORE on Post Operative Day 2 
TEMPORAL 
 
Figure 21Post operative Day 2, Temporal 
Pearson CHI2 (1) =   1.2131   P Value = 0.271 
Fisher's exact =                 0.366 
1-sided Fisher's exact =                 0.278 
 
 
HOUSE–BRACKMANN SCORE on Post Operative Day 2 
MANDIBULAR 
 
 
Figure 22: Post operative Day 2, Mandibular 
Pearson CHI2(1) =   0.6980   P Value = 0.403 
Fisher's exact =                 0.670 
 1-sided Fisher's exact =                 0.348  
 
POD 2 T  SP EC TOTAL
MILD 15 13 28
% 78.95 92.86 84.85
MODERATE & SEVERE 4 1 5
% 21.05 7.14 15.15
TOTAL 19 14 33
100% 100% 100%
POD 2 M  SP EC TOTAL
MILD 14 12 26
% 73.68 85.71 78.79
MODERATE & SEVERE 5 2 7
% 26.32 14.29 21.21
TOTAL 19 14 33
100% 100% 100%
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HOUSE–BRACKMANN SCORE on Post Operative Day 7 
ZYGOMATIC 
 
 
Figure 23: Post operative Day 7, Zygomatic 
Pearson CHI2 (1) =   0.5658   P Value = 0.452 
Fisher's exact =        0.620 
1-sided Fisher's exact =   0.426 
 
HOUSE–BRACKMANN SCORE on Post Operative Day 7 
TEMPORAL 
 
Figure 24: Post operative Day 7, Temporal 
Pearson CHI2 (1) =   1.2131   P Value = 0.271 
Fisher's exact =      0.366 
1-sided Fisher's exact =                 0.278 
 
POD 7 Z  SP EC TOTAL
MILD 16 13 29
% 84.21 92.86 87.88
MODERATE & SEVERE 3 1 4
% 15.79 7.14 12.12
TOTAL 19 14 33
100% 100% 100%
POD 7 T  SP EC TOTAL
MILD 15 13 28
% 78.95 92.86 84.85
MODERATE & SEVERE 4 1 5
% 21.05 7.14 15.15
TOTAL 19 14 33
100% 100% 100%
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HOUSE–BRACKMANN SCORE on Post Operative Day 7 
MANDIBULAR 
 
 
Figure 25: Post Operative Day 7, Mandibular 
Pearson CHI2 (1) =   0.6980   P Value = 0.403 
Fisher's exact =    0.670 
1-sided Fisher's exact =                 0.348 
 
HOUSE–BRACKMANN SCORE on Post Operative Day 10 
ZYGOMATIC 
 
 
Figure 26: Post operative Day 10, Zygomatic 
Pearson CHI2 (1) =   0.1117   P Value = 0.738 
Fisher's exact =      1.000 
1-sided Fisher's exact =                 0.616 
POD 7 M  SP EC TOTAL
MILD 14 12 26
% 73.68 85.71 78.79
MODERATE & SEVERE 5 2 7
% 26.32 14.29 21.21
TOTAL 19 14 33
100% 100% 100%
POD 10 Z  SP EC TOTAL
MILD 17 13 30
% 89.47 92.86 91.91
MODERATE & SEVERE 2 1 3
% 10.53 7.14 9.09
TOTAL 19 14 33
100% 100% 100%
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HOUSE–BRACKMANN SCORE on Post Operative Day 10 
TEMPORAL 
 
Figure 27: post operative Day 10, Temporal 
Pearson CHI2 (1) =   0.5658   P Value = 0.452 
Fisher's exact =  0.620 
1-sided Fisher's exact =                 0.426 
 
HOUSE–BRACKMANN SCORE on Post Operative Day 10 
MANDIBULAR 
 
Figure 28: Post operative Day 10, Mandibular 
 
Pearson CHI2 (1) =   0.6980   P Value = 0.403 
Fisher's exact =    0.670 
1-sided Fisher's exact =                 0.348 
POD 10 T  SP EC TOTAL
MILD 16 13 29
% 84.21 92.86 87.88
MODERATE & SEVERE 3 1 4
% 15.79 7.14 12.12
TOTAL 19 14 33
100% 100% 100%
POD 10 M  SP EC TOTAL
MILD 14 12 26
% 73.68 85.71 78.79
MODERATE & SEVERE 5 2 7
% 26.32 14.29 21.21
TOTAL 19 14 33
100% 100% 100%
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The above results were not statistically significant. Further Analysis of the above 
results revealed the following: 
 
Figure 29: Post Operative Day 2, Mild Symptoms 
There was an increased incidence of mild facial nerve palsy in Temporal, 
Zygomatic and Mandibular branches in Extracapsular Excision as compared to 
Superficial Parotidectomy on Day 2.  
  
POD 2 MILD
SP EC
T 78.95 92.86
Z 84.21 92.86
M 73.68 85.71
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POD 2  M & S   
  SP EC 
T 21.05 7.14 
Z 15.79 7.14 
M 26.32 14.29 
 
Figure 30: Post operative Day 2, Moderate & Severe Symptoms 
There was a decreased incidence of moderate facial nerve palsy in Temporal, 
Zygomatic and Mandibular branches in Extracapsular excision as compared to 
superficial parotidectomy on Day 2. This incidence was more for Mandibular than 
Temporal and Zygomatic branches.  
 
POD 7 MILD   
  SP EC 
T 78.95 92.86 
Z 84.21 92.86 
M 73.68 85.71 
 
Figure 31: Post operative Day 7, Mild Symptoms 
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There was an increased incidence of mild facial nerve palsy in Temporal, 
Zygomatic and Mandibular branches in Extracapsular Excision as compared to 
Superficial Parotidectomy on Day 7.  
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POD 7 M & S   
  SP EC 
T 21.05 7.14 
Z 15.79 7.14 
M 26.32 14.29 
 
Figure 32: Post operative Day 7, Moderate & Severe Symptoms 
 
There was a decreased incidence of moderate facial nerve palsy in Temporal, 
Zygomatic and Mandibular branches in Extracapsular excision as compared to 
superficial parotidectomy on Day 7. This incidence was more for Mandibular than 
Temporal and Zygomatic branches. 
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POD 10 MILD   
  SP EC 
T 84.21 92.86 
Z 89.47 92.86 
M 73.68 85.71 
 
Figure 33: Post Operative Day 10, Mild Symptoms 
There was an increased incidence of mild facial nerve palsy in Temporal, 
Zygomatic and Mandibular branches in Extracapsular Excision as compared to 
Superficial Parotidectomy on Day 10.  
 
 
POD 10 M & S   
  SP EC 
T 15.79 7.14 
Z 10.53 7.14 
M 26.32 14.29 
 
Figure 34: Post operative Day 10, Moderate & Severe Symptoms 
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There was a decreased incidence of moderate facial nerve palsy in Temporal, 
Zygomatic and Mandibular branches in Extracapsular excision as compared to 
superficial parotidectomy on Day 10. This incidence was more for Mandibular 
than Temporal and Zygomatic branches.  
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DISCUSSION 
  
 
 
77 
 
DISCUSSION 
  
 In this study, the demographic data and clinical features of parotid tumors 
were analyzed.  Two operations for benign parotid tumors: Superficial 
Parotidectomy and Extracapsular Excision were compared and were analyzed for 
margin status and post operative facial nerve palsy.  
 There was no gender predominance and the maximum number of 
participants in this study were from the 40-49 year age group.  Clinically, it was 
predominantly painless, spherical in nature with a smooth consistency.  
Margins 
 An adequate margin of 4mm was not achieved in 63 % of superficial 
parotidectomy and 64.28% of Extracapsular Excision operations.  In superficial 
parotidectomy, this could be due to the tumor being close to the facial nerve and 
fine dissection to spare the nerve could not produce an adequate margin.  The 
same reason could apply to Extracapsular Excision in cases of tumors lying close 
to the facial nerve. The margin was not breached in either of the groups. 
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House-Brackmann Score 
 There was no statistically significant difference in the morbidity of early 
facial nerve palsy between the two groups in the first 10 post operative days.  
However there was an increased incidence of mild facial nerve palsy in patients 
who underwent extracapsular excision on each of the days 2, 7 and 10 post 
operatively.  There was, in contrast, an increased incidence of moderate and 
severe facial nerve palsy in patients who underwent superficial parotidectomy.  
The significance of the above could be improved by recruiting larger numbers.  
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CONCLUSION 
1. There was a decreased incidence of mild facial nerve palsy in the post 
operative period in patients who underwent Superficial Parotidectomy as 
compared to those who underwent Extracapsular excision.  However, there 
was an increased incidence of  moderate and severe facial nerve paralysis 
in the immediate post operative period in patients who underwent 
superficial parotidectomy as compared to those who underwent 
extracapsular excision. The above facts were not statistically significant.   
2. The positive margins associated with extracapsular excision were similar to 
that of superficial parotidectomy in this study, but this was not statistically 
significant.  
3. Extracapsular Excision could be considered an alternative to Superficial 
Parotidectomy in treatment of benign parotid tumors, but larger numbers 
are required to statistically confirm the same.  
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LIMITATIONS  
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LIMITATIONS 
 Our calculated sample size was 44 but during the course of the study 36 
cases were studied.  It is planned to continue to recruit patients beyond the 
stipulated time frame, to get statistically significant results. 
 Long term incidence rate of facial nerve palsy was not compared within the 
scope of this study.  The patients are kept under follow up to identify the 
same.  
 Recurrence rates between the two procedures were not compared. It is 
planned to document the same during follow up of these patients.  
 The cosmetic advantage provided by extracapsular excision was not 
quantified. Prevention of a hollow in the operated site and a smaller scar 
may be of importance to some sectors of the population for whom 
extracapsular excision could be a viable option.  
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ANNEXURE 
Thesis Profoma 
 
Serial Number:___________                                                                                   Date:_________ 
Name_____________________________________________________________________ 
Hospital Number_____________   Age:___Sex: M/F 
Address:___________________________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
Telephone:_________________ Cell Phone:______________________Other:____________ 
 
1. Duration_______________months/years 
2. Site: Right / Left 
3. Pain: Yes / No 
4. Previous Operation: Yes / No 
5. Extent:____________________________________ Size: _________cm 
Shape:________________________ Surface:_____________________  
Edge:_________________________ Consistency: Soft / Cystic / Hard 
6. Fixity to skin: Fixed /Not Fixed 
7. Fixity to Masseter: Fixed / Not Fixed 
8. Enlargement of Deep Lobe: Yes / No 
9. Facial Nerve Palsy: House Brackmann Score: 
Temporal: __________Zygomatic:_______________Buccal___________________ 
10. Lymph Node Enlargement: Present/Absent 
11. Restricted Jaw Movements: Present / Absent 
 
 
92 
 
 
FNAC Report: 
12. Cells: Sufficient/Insufficient 
13. Impression: Benign/Malignant 
_____________________________________________________ 
 
Ultrasonography Findings: 
14. Tumour Size__________ Shape________________ 
15. Borders: Capsule irregular / well defined 
16. Contents: Heterogeneous / Homogenous 
17. Contents: Cystic  / Solid 
18. Distance between tumour and RMV:_________ 
19. Increased Vascularity on Doppler: Yes / No 
20. Distance of the tumour from the styloid process: ________ 
 
Other Investigations: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
Type of Procedure Proposed: Superficial Parotidectomy / Extracapsular Excision 
Intra Op Findings: 
Facial Nerve involved: Yes / No 
Nodes present: Yes / No 
Size: 
Cystic: Yes / No 
Final Report: 
Surgical Margins: Inadequate / Adequate 
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Patient Information Sheet 
 
Evaluation of Extracapsular Excision in the management of Benign Parotid 
Tumors 
 
Patient Information Sheet 
Study Co-coordinator: Dr. Aditya Benjamin 
Dept. of General Surgery 
CMC Vellore 
This is the form for giving consent to participate in the aforementioned study, which seeks to evaluate the 
procedure of Extracapsular Excision, for treatment of benign parotid tumors, in comparison to the procedure of 
Superficial Parotidectomy.  
You have been diagnosed to have a benign parotid tumour. It is managed by removal of the superficial part of the 
parotid gland with the tumour. As means to reduce the post operative consequences of this operation, a  more 
limited removal of your parotid gland without compromising principles of cancer surgery is going to be 
administered upon you with your permission. There is evidence which suggests that this procedure is safe with 
lesser complications and better acceptability in patients studied elsewhere in the world. We want to adopt this 
technique for which we will need preliminary investigations in a certain number of patients before adopting as a 
standard of care. With your kind permission we would like to enroll you into our study. 
The procedures being done: 
There are two procedures being evaluated in this study: Extracapsular Excision and Superficial Parotidectomy. 
Superficial Parotidectomy is a standard procedure, where the entire Superficial Lobe of the Parotid Gland in which 
the tumour is present, would be excised. The tumour would be removed along with the gland. The side effects of 
this procedure can include: 
Early side effects: 
• Weakness in forehead wrinkling on affected side , weakness in closing eye on affected side, weakness in 
cheek movement on affected side, dribbling of saliva on affected side, and lack of or altered facial 
expressions. 
• A collection of blood or fluid in the operated site 
• Cosmetic Defect of a scar on the side of the face, and in some cases, a depression behind the jaw-bone  
Late complications 
• Weakness of face muscles  
• A collection of saliva in the operated site 
•  Lack of sensation on the operated site 
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• Symptoms of sweating while chewing food 
• Discharge of saliva from an opening in the operated site.  
The alternative procedure is Extracapsular Dissection, where the tumour would be removed along with a  margin 
of normal tissue around the tumour.  The complications expected from this procedure are:  
• Weakness in forehead wrinkling on affected side , weakness in closing eye on affected side, weakness in 
cheek movement on affected side, dribbling of saliva on affected side, and lack of or altered facial 
expressions. 
 A collection of blood or fluid in the operated site 
 Cosmetic Defect of a scar on the side of the face 
 A collection of saliva in the operated site 
 Discharge of saliva from an opening in the operated site.  
 Lack of sensation on the operated site 
 
How the patients are going to be chosen: 
There are two groups of patients in this study. One group will undergo Superficial Parotidectomy, and the other 
group will undergo Extracapsular Excision. You will be chosen to either one of the groups depending on a random 
code generated by a computer software.  
At any given point in this treatment if it is felt that this procedure is going to be inadequate, the standard 
procedure is going to be adopted without compromising the principles of cancer surgery.   
In case of any doubts, please contact Dr. Aditya Benjamin at 9655726381  
Office Number: (Surgery 1 Office): 04162282082 
 
I hereby agree to participate in the study: Evaluation of Extracapsular Excision in the treatment of benign parotid 
tumors. 
Signed: 
Study Participant:  
Date: 
Witness: 
Date: 
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Informed Consent Form 
Informed Consent form to participate in a clinical trial 
Christian Medical College, Vellore 
Department of General Surgery 
Evaluation of Extracapsular Excision in the management of benign parotid tumors 
 
Study Number:  
Subject’s Name:  
Date of Birth / Age: 
 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions.  
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected.  
(iii) I understand that the investigators of this study, the Ethics Committee and the regulatory 
authorities will not need my permission to look at my health records both in respect of the 
current study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my identity will not 
be revealed in any information released to third parties or published.  
(iv) I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s)  
(v) I agree to take part in the above study.  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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Data Sheet 
Randomization Code 
 
Figure 35: Randomization Code 
1= EXTRACAPSULAR EXCISION, 2 = SUPERFICIAL PAROTIDECTOMY 
1 1
2 2
3 1
4 2
5 2
6 2
7 2
8 1
9 1
10 1
11 2
12 1
13 2
14 2
15 1
16 1
17 1
18 1
19 2
20 1
21 2
22 2
23 1
24 2
25 1
26 1
27 2
28 2
29 1
30 2
31 2
32 2
33 1
34 1
35 1
36 1
37 2
38 2
39 2
40 2
41 1
42 1
43 2
44 1
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MASTER CHART 
 
Figure 36: Master Chart 
HOUSE BRACKMAN SCORES AT 2, 7 AND 10 DAYS 
 
Figure 37: House Brackmann Scores at 2, 7 and 10 days 
identifier age gender duration months site pain previous size x shape surface edge consistencfixity fixity1 enlargemenpre pre1 pre2 lymph restricted cells impressionoperation facial nodes size1 cystic final surgical
1 7 1 3 0 1 2 2 50 50 1 1 1 2 2 2 2 1 1 1 2 2 0 0 1 2 1 4 1 1 2
2 6 1 12 0 1 2 2 30 30 1 1 1 2 2 2 2 1 1 1 2 2 1 1 1 2 2 2 2 1 1
3 3 1 2 0 2 2 2 55 50 1 1 1 2 2 2 2 1 1 1 2 2 1 1 1 2 1 4 2 1 3
4 4 1 0 9 2 2 2 60 50 2 2 1 2 2 2 2 1 1 1 2 2 0 0 1 2 6 2 1 1
5 3 2 3 0 2 2 2 25 25 1 1 1 2 2 2 2 1 1 1 2 2 0 0 1 2 2 2 2 1 3
6 2 1 4 0 1 2 2 90 80 2 2 2 2 2 2 2 1 1 1 2 2 1 1 1 2 2 8 2 1 1
7 4 2 4 0 1 2 2 50 60 1 1 1 2 2 2 2 1 1 1 2 2 0 0 1 2 2 3 2 1 2
8 3 1 1 6 2 2 2 50 60 1 1 1 2 2 2 2 1 1 1 2 2 0 0 1 2 1 3 2 1 3
9 4 1 1 0 1 2 2 30 20 1 1 1 2 2 2 2 1 1 1 2 2 0 0 1 2 2 2 2 1 2
10 5 2 1 0 1 2 2 30 20 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 2 1 2 2 1 3
11 6 2 1 6 1 2 2 50 50 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 2 2 3 2 1 1
12 5 2 2 0 2 2 2 30 20 1 1 1 2 2 2 2 1 1 1 2 2 1 1 1 2 2 2 2 1 1
13 5 2 9 0 2 2 2 30 20 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 1 2 2 2 1 2
14 5 1 1 0 2 2 2 20 20 1 2 1 2 2 2 2 1 1 1 2 2 1 1 2 2 2 1 2 1 3
15 7 2 1 0 2 2 2 10 5 1 1 1 2 2 2 2 1 1 1 2 2 0 0 2 2 1 1 1 2 1
16 5 2 0 6 1 2 2 25 25 1 1 1 2 2 2 2 1 1 1 2 2 1 1 2 1 2 2 2 1 0
17 6 1 4 0 2 2 2 25 25 1 1 1 2 2 2 2 1 1 1 2 2 1 1 2 2 2 2 2 1 3
18 6 2 0 6 2 2 2 20 20 1 1 1 1 2 2 2 1 1 1 2 2 1 1 2 2 2 2 1 1 2
19 6 1 3 0 2 2 2 30 20 1 2 1 2 2 2 2 1 1 1 2 2 1 1 2 2 2 2 2 1 1
20 2 2 0 8 1 1 2 20 20 1 2 1 2 2 2 2 1 1 1 2 2 1 1 2 2 1 1 2 1 2
21 6 2 15 0 2 2 2 30 30 1 1 1 2 2 2 2 1 1 1 2 2 1 1 2 2 2 3 2 1 2
22 3 1 8 0 2 2 2 35 35 1 2 1 2 2 2 2 1 1 1 2 2 1 1 2 2 1 2 2 1 1
23 2 2 1 0 2 2 2 60 40 1 2 1 2 2 2 2 1 1 1 2 2 1 1 2 1 1 4 2 1 1
24 2 1 0 6 1 2 2 20 20 1 2 2 2 2 2 2 1 1 1 2 2 1 1 2 2 2 3 2 1 1
25 5 2 1 0 2 2 2 30 30 1 2 2 2 2 2 2 1 1 1 2 2 2 1 2 2 2 2 1 1
26 5 2 3 0 1 2 2 40 30 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 1 2 5 2 1 1
27 4 1 7 0 1 2 2 40 30 1 1 2 2 2 2 2 1 1 1 2 2 0 0 1 2 1 4 2 1 1
28 5 1 0 6 2 2 2 40 30 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 2 1 5 2 1 2
29 3 2 4 0 1 2 2 30 25 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 2 2 4 2 1 1
33 4 2 1 0 1 2 2 20 20 1 2 1 2 2 2 2 1 1 1 2 2 2 0 2 2 2 3 2 1 0
34 5 2 3 0 1 2 2 30 30 1 2 1 2 1 2 2 1 1 1 2 2 1 1 2 2 2 2 2 1 1
35 4 2 0 9 2 2 2 30 30 1 1 1 2 2 2 2 1 1 1 2 2 1 1 1 2 2 3 2 1 2
36 5 1 0 4 1 2 2 40 40 1 2 1 2 2 2 2 1 1 1 2 2 1 1 1 2 2 4 2 1 2
identifier Group POD2 T POD2 Z POD2 M POD7 T POD7 Z POD 7 M POD10 T POD10Z POD10M
1 1 2 1 1 2 1 1 2 1 1
2 1 3 2 3 3 2 3 3 2 3
3 1 1 1 1 1 1 1 1 1 1
4 1 1 1 1 1 1 1 1 1 1
5 1 1 1 1 1 1 1 1 1 1
6 1 1 1 2 1 1 2 1 1 2
7 1 1 3 3 1 3 3 1 2 3
8 1 1 1 2 1 1 2 1 1 2
9 1 1 1 1 1 1 1 1 1 1
10 1 1 1 2 1 1 1 1 1 1
11 1 1 1 1 1 1 1 1 1 1
12 1 1 1 2 1 1 2 1 1 2
13 1 3 3 3 3 3 3 3 3 3
14 2 1 1 1 1 1 1 1 1 1
15 2 1 1 1 1 1 1 1 1 1
16 2 1 1 1 1 1 1 1 1 1
17 2 1 1 1 1 1 1 1 1 1
18 2 1 1 1 1 1 1 1 1 1
19 2 1 1 1 1 1 1 1 1 1
20 2 1 1 1 1 1 1 1 1 1
21 2 1 1 1 1 1 1 1 1 1
22 2 1 1 1 1 1 1 1 1 1
23 2 5 3 5 5 3 5 5 3 5
24 2 1 1 1 1 1 1 1 1 1
25 2 1 1 3 1 1 3 1 1 3
26 1 3 2 3 3 2 3 2 2 3
27 1 1 1 2 1 1 2 1 1 2
28 1 1 2 2 1 2 2 1 2 2
29 1 3 3 4 3 3 4 3 3 4
33 2 1 1 1 1 1 1 1 1 1
34 2 1 1 1 1 1 1 1 1 1
35 1 1 1 2 1 1 2 1 1 2
36 1 1 1 1 1 1 1 1 1 1
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Images 
 
Extracapsular Excision 
 
 
 
 
Figure 38: Cervico-mastoid component of Modified Blair's Incision 
(Extracapsular Excision) 
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Extracapsular Excision 
 
 
 
 
Figure 39: Dissecting Parotid Fascia 
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Extracapsular Excision 
 
 
 
 
Figure 40: Seperation of Fascia 
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Extracapsular Excision 
 
 
 
 
Figure 41: Excision of tumor 
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Extracapsular Excision 
 
 
 
Figure 42: Tumor bed after excision 
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Assessing House Brackmann Score Post operatively 
 
 
 
Figure 43: Temporalis Function (T = 1) 
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POST OPERATIVE HOUSE BRACKMANN SCORE 
 
 
Figure 44: Zygomatic Function (Z = 1) 
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POST OPERATIVE HOUSE BRACKMANN SCORE 
 
 
 
 
 
 
Figure 45: Mandibular function (M = 1) 
 
  
 
 
107 
 
 
POST OPERATIVE HOUSE BRACKMANN SCORE 
 
 
 
 
 
Figure 46: Post Operative House-Brackmann Score (T=2) 
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POST OPERATIVE HOUSE BRACKMANN SCORE 
 
 
 
 
 
Figure 47: Post operative House-Brackmann Score (Z=1) 
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POST OPERATIVE HOUSE BRACKMAN SCORE 
 
 
 
Figure 48: Post Operative House-Brackmann Score (M = 3) 
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Figure 49: Post operative scar following superficial parotidectomy 
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Figure 50: Post operative Scar following extracapsular excision 
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Figure 51: Specimen with intact capsule 
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